Travere Therapeutics, Inc. TVTX Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s accrued expenses and other liabilities?
- Travere Therapeutics, Inc. (TVTX) reported accrued expenses and other liabilities of -$20.9M in Q1 2026.
- How has Travere Therapeutics, Inc.'s accrued expenses and other liabilities changed year-over-year?
- Travere Therapeutics, Inc.'s accrued expenses and other liabilities decreased by 119.1% year-over-year, from -$9.54M to -$20.9M.
- What is the long-term trend for Travere Therapeutics, Inc.'s accrued expenses and other liabilities?
- Over 2 years (2021 to 2025), Travere Therapeutics, Inc.'s accrued expenses and other liabilities has grown at a 31.5% compound annual growth rate (CAGR), from $16.68M to $28.84M.